Patented biomarker for cardiac injury. 

Patented biomarker for cardiac injury. 

Category: Abstracts

Incorporating cMyBP-C and hs-cTnT - effectively rules out AMI, showing non-inferiority to hs-cTnT-only-based rapid rule-out algorithms and offers a promising alternative, potentially enhancing clinical decision-making in emergency settings.
Changes in levels of the novel biomarker cMyC was signi cantly associated with hs-cTnI plasma levels in patients with symptomatic chronic HFrEF during a structured 12 week exercise training program. Being more sensitive, it may indicate a role as a future marker of subclinical myocardial damage.
When compared with high-sensitivity troponin, cMyC concentrations showed greater interindividual variability and rose to a level that was statistically distinguishable from baseline at the 3 hour timepoint, as opposed to 5 hours for the more established biomarker, high-sensitivity troponin.
We have previously shown that significant circadian oscillations exist for cardiac troponin T (cTnT) but not for cardiac troponin I (cTnI). Cardiac myosin-binding protein C (cMyC) is a novel protein biomarker of myocardial injury with a promising role in the diagnosis and risk stratification of acute myocardial injury. In this study, we examine and compare the diurnal variation of cMyC with cTnT/I.
Phosphorylation and fragmentation pattern of cMyC are dependent on the type of myocardial injury and might aid the differentiation between Type-1 and non-Type-1 AMI.